Liver MRI for Colorectal Cancer Liver Metastasis: Comparative Effectiveness Research for the Choice of Contrast Agents
试验速览
- 阶段
- 不适用
- 入组人数
- 500
- 主要终点
- Disease free survival
研究概览
简要总结
Magnetic resonance imaging (MRI) has been widely used for problem-solving tool in the evaluation of hepatic lesions, and it has been shown to have better sensitivity than CT for detection of colorectal liver metastases, especially for lesions which are smaller than 1 cm. After introduction of a liver-specific hepatobiliary MR contrast agent, gadoxetic acid, gadoxetic acid-enhanced MRI (Gd-EOB-MRI) has been increasingly used for evaluation of liver lesion including CRLM. However, compared to conventional MRI with extracellular contrast agent (ECA-MRI), Gd-EOB-MRI has different pharmacodynamic characteristics, and is more expensive due to higher cost of gadoxetic acid and needs longer scan time to obtain hepatobiliary phase which is generally acquired 15 to 20 minutes after contrast injection. The purpose of this study was to compare the clinical outcome and diagnostic performance of Gd-EOB-MRI and ECA-MRI for evaluation of focal hepatic lesion in newly diagnosed colorectal cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with surgically proven colorectal adenocarcinoma
- •patients who underwent abdominopelvic CT and liver MRI for initial staging before any treatment
- •no past or concurrent malignancy other than colorectal adenocarcinoma.
排除标准
- •precontrast abdominopelvic CT
- •precontrast liver MRI
- •liver MRI using contrast other than extracellular agent or gadoxetic acid
- •the interval between CT and liver MRI was longer than 4 weeks
- •patients who had suspected multiple hepatic metastases (> 10) on CT
- •distant metastasis other than liver and
- •unavailable reference standard of their hepatic lesions with no pathologic confirmation or follow up imaging.
结局指标
主要结局
Disease free survival
时间窗: up to 120 months
From date of curative hepatic surgery until the date of first documented tumor recurrence or date of death from disease-related cause
次要结局
未报告次要终点